In this program, experts in the field will address important, yet often controversial, topics in the management of patients with cholangiopathies. The session will focus in particular on primary sclerosing cholangitis (PSC). Clinicians will learn about emerging developments in potential medical therapies, as well as improved monitoring techniques and surveillance strategies for the ongoing care of their patients.
This SIG reveals recent progress made in liver fibrosis related to NASH, including new molecular mechanisms and translational aspects of NASH-mediated fibrosis and cirrhosis, and translation of laboratory findings into humans. Speakers will cover significant new information about the potential role of hepatocytes, crosstalk with non-parenchymal cells in NASH-fibrosis, and potential non-invasive biomarkers and treatments of patients with NASH-fibrosis.
Explore critical, clinically relevant topics related to basic mechanisms of hepatotoxicity at this SIG. Each talk begins with a patient case presented by a trainee. Discussion topics include how the hepatocyte responds to stress, including antibiotics and other medications; the genetic and epigenetic basis of drug-induced liver injury; and the interplay of adaptive immunity and liver injury.
This program will summarize key concepts in U.S. and global strategies to achieve hepatitis C elimination. Experts will address topics such as new universal screening recommendations, novel paradigms for care delivery beyond the specialty clinic, global strategies for microelimination, treatment as prevention in persons who inject drugs (PWID), and the latest updates on HCV vaccine development.
Takashi Kokudo – 13 November 2020
Harel Dahari, Andrew Vaillant, Scott J. Cotler – 13 November 2020
Zoe N. Memel, Ashwini Arvind, Oluwatoba Moninuola, Lisa Philpotts, Raymond T. Chung, Kathleen E. Corey, Tracey G. Simon – 13 November 2020 – Hepatocellular carcinoma (HCC) is the third‐leading cause of cancer‐related death worldwide, with a growing incidence and poor prognosis. While some recent studies suggest an inverse association between aspirin use and reduced HCC incidence, other data are conflicting. To date, the precise magnitude of risk reduction—and whether there are dose‐dependent and duration‐dependent associations—remains unclear.
Laura J. Kitto, Neil C. Henderson – 13 November 2020 – The hepatic mesenchyme has been studied extensively in the context of liver fibrosis; however, much less is known regarding the role of mesenchymal cells during liver regeneration. As our knowledge of the cellular and molecular mechanisms driving hepatic regeneration deepens, the key role of the mesenchymal compartment during the regenerative response has been increasingly appreciated.
Véronique Loustaud‐Ratti, Alicia Anneraud, Paul Carrier, Marilyne Debette‐Gratien, Anne De Muret, Mattias Tallegas, Hélène Barraud, Louise Barbier, Ephrem Salamé – 13 November 2020